Biohaven CEO Vlad Coric talks to Pharm Exec about NURTEC ODT’s swift and seismic impact on the migraine market.
Closing the gaps in complex therapy data remains a hurdle, but “getting clever” with AI can offer a path forward.
How Gilead readied remdesivir for the COVID challenge.
How the UK is making progress in this hi-tech field.
Looking Back at 1997–1999.
Amgen is collaborating on two digital health initiatives aimed at improving heart failure care and rehabilitation.